Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis

Oncogene

Volumn 33, Issue 17, 2014, Pages 2264-2272

  Foley, C J ^a   Fanjul Fernandez M ^b   Bohm, A ^a   Nguyen, N ^a   Agarwal, A ^a   Austin, K ^a   Koukos, G ^a   Covic, L ^a   Lopez Otin C ^b   Kuliopulos, A ^a  

^a TUFTS UNIVERSITY   (United States)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

angiogenesis; lung cancer; MMP1; Mmp1a; PAR1

Indexed keywords

INTERSTITIAL COLLAGENASE; PROTEINASE ACTIVATED RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CATALYSIS; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALIA; MUS;

AMINO ACID SEQUENCE; ANIMALS; CARCINOGENESIS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME PRECURSORS; FEMALE; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 1; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN SORTING SIGNALS; TUMOR BURDEN;

EID: 84899618978     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.157     Document Type: Article

References (43)

1. Boström P, Sö derström M, Vahlberg T, Sö derström K-O, Roberts PJ, Carpén O et al. MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer 2011; 11: 348.
2. Smith V, Wirth GJ, Fiebig HH, Burger AM. Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genom Proteom 2008; 5: 263-273.
3. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 1999; 59: 4225-4227.
4. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri V-M, Pyrhönen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002; 97: 432-438.
5. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase- 1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461-462.
6. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol 1998; 185: 256-261.
7. Goldberg GI, Wilhelm SM, Kronberger A, Bauer EA, Grant GA, Eisen AZ. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. J Biol Chem 1986; 261: 6600-6605.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
9. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120: 303-313.
10. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metast Rev 2006; 25: 9-34.
11. Eck SM, Blackburn JS, Schmucker AC, Burrage PS, Brinckerhoff CE. Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun 2009; 33: 214-221.
12. Tressel SL, Kaneider NC, Kasuda S, Foley C, Koukos G, Austin K et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 2011; 3: 370-384.
13. Bolon I, Gouyer V, Devouassoux M, Vandenbunder B, Wernert N, Moro D et al. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 1995; 147: 1298-1310.
14. Ito M, Ishii G, Nagai K, Maeda R, Nakano Y, Ochiai A. Prognostic impact of cancerassociated stromal cells in stage I lung adenocarcinoma patients. Chest 2012; 142: 151-158.
15. Saarinen J, Welgus HG, Flizar CA, Kalkkinen N, Helin J. N-glycan structures of matrix metalloproteinase-1 derived from human fibroblasts and from HT-1080 fibrosarcoma cells. Eur J Biochem 1999; 259: 829-840.
16. Balbn M, Fueyo A, Knäuper V, López JM, Alvarez J, Sánchez LM et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 2001; 276: 10253-10262.
17. Nuttall RK, Sampieri CL, Pennington CJ, Gill SE, Schultz GA, Edwards DR. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563: 129-134.
18. Hartenstein B, Dittrich BT, Stickens D, Heyer B, Vu TH, Teurich S et al. Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice. J Invest Dermatol 2006; 126: 486-496.
19. Pfaffen S, Hemmerle T, Weber M, Neri D. Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3. Exp Cell Res 2010; 316: 836-847.
20. Balbn M, Fueyo A, Tester AM, Pendá s AM, Pitiot AS, Astudillo A et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003; 35: 252-257.
21. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004; 131: 5883-5895.
22. Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, Lopez-Otin C et al. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA 2004; 101: 17192-17197.
23. Bertram JS, Janik P. Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett 1980; 11: 63-73.
24. Goerge T, Barg A, Schnaeker E-M, Poppelmann B, Shpacovitch V, Rattenholl A et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinaseactivated receptor 1 promoting endothelial cell activation. Cancer Res 2006; 66: 7766-7774.
25. Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L et al. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 2010; 70: 5880-5890.
26. Blackburn JS, Brinckerhoff CE. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am J Pathol 2008; 173: 1736-1746.
27. Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G et al. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Therap 2008; 7: 2746-2757.
28. Cisowski J, O'Callaghan K, Kuliopulos A, Yang J, Nguyen N, Deng Q et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol 2011; 179: 513-523.
29. Foley CJ, Luo C, O'Callaghan K, Hinds PW, Covic L, Kuliopulos A. Matrix metalloprotease- 1a promotes tumorigenesis and metastasis. J Biol Chem 2012; 287: 24330-24338.
30. Jozic D, Bourenkov G, Lim N-H, Visse R, Nagase H, Bode W et al. X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. J Biol Chem 2005; 280: 9578-9585.
31. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87: 5578-5582.
32. Nguyen N, Kuliopulos A, Graham RA, Covic L. Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res 2006; 66: 2658-2665.
33. Vizoso FJ, González LO, Corte MD, Rodrguez JC, Vázquez J, Lamelas ML et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007; 96: 903-911.
34. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloprotease family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-282.
35. Griffin CT, Srinivasan Y, Zheng Y-W, Huang W, Coughlin SRA. Role for thrombin receptor signaling in endothelial cells during embryonic development. Science 2001; 293: 1666-1670.
36. Odake S, Morita Y, Morikawa T, Yoshida N, Hori H, Nagai Y. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids. Biochem Biophys Res Commun 1994; 199: 1442-1446.
37. Vanlaere I, Libert C. Matrix metalloproteinases as drug targets in infections caused by Gram-negative bacteria and in septic shock. Clin Microbiol Rev 2009; 22: 224-239.
38. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-557.
39. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994; 269: 25742-25746.
40. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276: 43503-43508.
41. Ito A, Mukaiyama A, Itoh Y, Nagase H, Thogersen IB, Enghild JJ et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 1996; 271: 14657-14660.
42. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998; 161: 3340-3346.
43. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003; 31: 3381-3385.